Is MDXH or CODX more profitable?

MDxHealth has a net margin of -29.90% compared to Co-Diagnostics' net margin of -6,760.63%. MDxHealth's return on equity of 0.00% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets MDxHealth -29.90% N/A -22.51% Co-Diagnostics -6,760.63% -164.92% -141.15%

Does the media refer more to MDXH or CODX?

In the previous week, MDxHealth and MDxHealth both had 1 articles in the media. MDxHealth's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MDxHealth 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CODX or NEUP?

In the previous week, Co-Diagnostics and Co-Diagnostics both had 1 articles in the media. Co-Diagnostics' average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Neuphoria Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CODX or NXTC more profitable?

NextCure has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. NextCure's return on equity of -132.48% beat Co-Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Co-Diagnostics -6,760.63% -164.92% -141.15% NextCure N/A -132.48% -88.45%

Does the media prefer CODX or NXTC?

In the previous week, NextCure had 5 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for NextCure and 1 mentions for Co-Diagnostics. NextCure's average media sentiment score of 0.59 beat Co-Diagnostics' score of 0.00 indicating that NextCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NextCure 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Co-Diagnostics (CODX) Competitors

$1.52 +0.10 (+7.04%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$1.50 -0.02 (-1.32%)

As of 08/7/2026 07:59 PM Eastern

Compare

CODX vs. MDXH, NEUP, NXTC, ALLR, and MRKR

Should you buy Co-Diagnostics stock or one of its competitors? MarketBeat compares Co-Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Co-Diagnostics include MDxHealth (MDXH), Neuphoria Therapeutics (NEUP), NextCure (NXTC), Allarity Therapeutics (ALLR), and Marker Therapeutics (MRKR). These companies are all part of the "biotechnology" industry.

How does Co-Diagnostics compare to MDxHealth?

MDxHealth (NASDAQ:MDXH) and Co-Diagnostics (NASDAQ:CODX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

15.0% of Co-Diagnostics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 2.3% of Co-Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MDxHealth currently has a consensus target price of $3.50, indicating a potential upside of 659.22%. Co-Diagnostics has a consensus target price of $67.50, indicating a potential upside of 4,340.79%. Given Co-Diagnostics' higher probable upside, analysts clearly believe Co-Diagnostics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MDxHealth has higher revenue and earnings than Co-Diagnostics. MDxHealth is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.21	-$33.52M	-$0.65	N/A
Co-Diagnostics	$718.17K	7.80	-$46.90M	-$15.77	N/A

MDxHealth has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Co-Diagnostics has a beta of 2.87, indicating that its share price is 187% more volatile than the broader market.

MDxHealth has a net margin of -29.90% compared to Co-Diagnostics' net margin of -6,760.63%. MDxHealth's return on equity of 0.00% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-29.90%	N/A	-22.51%
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%

In the previous week, MDxHealth and MDxHealth both had 1 articles in the media. MDxHealth's average media sentiment score of 0.00 equaled Co-Diagnostics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MDxHealth	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MDxHealth beats Co-Diagnostics on 8 of the 14 factors compared between the two stocks.

How does Co-Diagnostics compare to Neuphoria Therapeutics?

Co-Diagnostics (NASDAQ:CODX) and Neuphoria Therapeutics (NASDAQ:NEUP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Neuphoria Therapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Neuphoria Therapeutics' return on equity of -76.93% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Neuphoria Therapeutics	N/A	-76.93%	-54.76%

In the previous week, Co-Diagnostics and Co-Diagnostics both had 1 articles in the media. Co-Diagnostics' average media sentiment score of 0.00 equaled Neuphoria Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Neuphoria Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Co-Diagnostics has a beta of 2.87, suggesting that its share price is 187% more volatile than the broader market. Comparatively, Neuphoria Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the broader market.

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Neuphoria Therapeutics has higher revenue and earnings than Co-Diagnostics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$718.17K	7.80	-$46.90M	-$15.77	N/A
Neuphoria Therapeutics	$15.65M	1.32	-$370K	-$11.06	N/A

Co-Diagnostics currently has a consensus price target of $67.50, indicating a potential upside of 4,340.79%. Neuphoria Therapeutics has a consensus price target of $21.00, indicating a potential upside of 449.74%. Given Co-Diagnostics' higher possible upside, equities analysts clearly believe Co-Diagnostics is more favorable than Neuphoria Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Neuphoria Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Neuphoria Therapeutics beats Co-Diagnostics on 7 of the 12 factors compared between the two stocks.

How does Co-Diagnostics compare to NextCure?

Co-Diagnostics (NASDAQ:CODX) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

NextCure has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. NextCure's return on equity of -132.48% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
NextCure	N/A	-132.48%	-88.45%

15.0% of Co-Diagnostics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 2.3% of Co-Diagnostics shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Co-Diagnostics has a beta of 2.87, meaning that its stock price is 187% more volatile than the broader market. Comparatively, NextCure has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market.

Co-Diagnostics currently has a consensus target price of $67.50, indicating a potential upside of 4,340.79%. NextCure has a consensus target price of $19.00, indicating a potential upside of 225.34%. Given Co-Diagnostics' higher probable upside, equities analysts clearly believe Co-Diagnostics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Co-Diagnostics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$718.17K	7.80	-$46.90M	-$15.77	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

In the previous week, NextCure had 5 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for NextCure and 1 mentions for Co-Diagnostics. NextCure's average media sentiment score of 0.59 beat Co-Diagnostics' score of 0.00 indicating that NextCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NextCure	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NextCure beats Co-Diagnostics on 10 of the 15 factors compared between the two stocks.

How does Co-Diagnostics compare to Allarity Therapeutics?

Co-Diagnostics (NASDAQ:CODX) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

Allarity Therapeutics has lower revenue, but higher earnings than Co-Diagnostics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$718.17K	7.80	-$46.90M	-$15.77	N/A
Allarity Therapeutics	$320K	69.11	-$11.23M	-$0.72	N/A

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 2.3% of Co-Diagnostics shares are held by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Co-Diagnostics presently has a consensus target price of $67.50, suggesting a potential upside of 4,340.79%. Allarity Therapeutics has a consensus target price of $10.25, suggesting a potential upside of 637.41%. Given Co-Diagnostics' higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Co-Diagnostics had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 1 mentions for Co-Diagnostics and 0 mentions for Allarity Therapeutics. Co-Diagnostics' average media sentiment score of 0.00 equaled Allarity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Co-Diagnostics	Neutral
Allarity Therapeutics	Neutral

Allarity Therapeutics has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,760.63%. Allarity Therapeutics' return on equity of -109.94% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Co-Diagnostics has a beta of 2.87, meaning that its stock price is 187% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market.

Summary

Co-Diagnostics beats Allarity Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Co-Diagnostics compare to Marker Therapeutics?

Co-Diagnostics (NASDAQ:CODX) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

Marker Therapeutics has lower revenue, but higher earnings than Co-Diagnostics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$718.17K	7.80	-$46.90M	-$15.77	N/A
Marker Therapeutics	N/A	N/A	-$12.16M	-$0.61	N/A

Co-Diagnostics currently has a consensus target price of $67.50, suggesting a potential upside of 4,340.79%. Marker Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 792.86%. Given Co-Diagnostics' higher possible upside, equities analysts plainly believe Co-Diagnostics is more favorable than Marker Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Co-Diagnostics had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Co-Diagnostics and 0 mentions for Marker Therapeutics. Co-Diagnostics' average media sentiment score of 0.00 equaled Marker Therapeutics'average media sentiment score.

Company	Overall Sentiment
Co-Diagnostics	Neutral
Marker Therapeutics	Neutral

Marker Therapeutics has a net margin of -343.03% compared to Co-Diagnostics' net margin of -6,760.63%. Marker Therapeutics' return on equity of -73.29% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,760.63%	-164.92%	-141.15%
Marker Therapeutics	-343.03%	-73.29%	-59.70%

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are held by institutional investors. 2.3% of Co-Diagnostics shares are held by company insiders. Comparatively, 5.7% of Marker Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Co-Diagnostics has a beta of 2.87, meaning that its stock price is 187% more volatile than the broader market. Comparatively, Marker Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Summary

Marker Therapeutics beats Co-Diagnostics on 9 of the 14 factors compared between the two stocks.

Get Co-Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CODX vs. The Competition

Export

Metric	Co-Diagnostics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.60M	$3.69B	$7.02B	$13.00B
Dividend Yield	N/A	3.76%	2.58%	10.20%
P/E Ratio	-0.10	9.02	271.11	25.19
Price / Sales	7.80	1,269.90	590.84	78.19
Price / Cash	N/A	102.35	71.81	50.72
Price / Book	0.17	18.10	13.25	6.22
Net Income	-$46.90M	-$13.25M	$3.45B	$342.66M
7 Day Performance	5.56%	6.24%	4.67%	4.41%
1 Month Performance	-42.42%	-3.50%	-1.28%	-1.10%
1 Year Performance	-80.08%	61.28%	77.33%	23.99%

Co-Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CODX Co-Diagnostics	1.4962 of 5 stars	$1.52 +7.0%	$67.50 +4,340.8%	-80.1%	$5.60M	$718.17K	N/A	100	Upcoming Earnings Gap Up
MDXH MDxHealth	2.0655 of 5 stars	$0.44 -2.9%	$3.50 +691.9%	-82.7%	$21.88M	$107.88M	N/A	300	News Coverage Upcoming Earnings Gap Up
NEUP Neuphoria Therapeutics	2.2468 of 5 stars	$3.89 -1.0%	$21.00 +439.8%	-48.6%	$21.01M	$15.65M	N/A	N/A
NXTC NextCure	4.0185 of 5 stars	$5.78 +31.4%	$19.00 +228.7%	+19.9%	$20.87M	N/A	N/A	90	Earnings Report Gap Down
ALLR Allarity Therapeutics	1.7134 of 5 stars	$1.31 +3.1%	$10.25 +682.4%	+43.3%	$20.84M	$320K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CODX) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Co-Diagnostics (CODX) Competitors

CODX vs. MDXH, NEUP, NXTC, ALLR, and MRKR

How does Co-Diagnostics compare to MDxHealth?

Summary

How does Co-Diagnostics compare to Neuphoria Therapeutics?

Summary

How does Co-Diagnostics compare to NextCure?

Summary

How does Co-Diagnostics compare to Allarity Therapeutics?

Summary

How does Co-Diagnostics compare to Marker Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Co-Diagnostics (CODX) Competitors

CODX vs. MDXH, NEUP, NXTC, ALLR, and MRKR

How does Co-Diagnostics compare to MDxHealth?

Do insiders & institutionals believe in MDXH or CODX?

Do analysts rate MDXH or CODX?

Which has higher earnings and valuation, MDXH or CODX?

Which has more risk & volatility, MDXH or CODX?

Is MDXH or CODX more profitable?

Does the media refer more to MDXH or CODX?

Summary

How does Co-Diagnostics compare to Neuphoria Therapeutics?

Is CODX or NEUP more profitable?

Does the media favor CODX or NEUP?

Which has more volatility & risk, CODX or NEUP?

Do insiders and institutionals believe in CODX or NEUP?

Which has higher earnings and valuation, CODX or NEUP?

Do analysts recommend CODX or NEUP?

Summary

How does Co-Diagnostics compare to NextCure?

Is CODX or NXTC more profitable?

Do insiders & institutionals believe in CODX or NXTC?

Which has more volatility & risk, CODX or NXTC?

Do analysts rate CODX or NXTC?

Which has higher valuation & earnings, CODX or NXTC?

Does the media prefer CODX or NXTC?

Summary

How does Co-Diagnostics compare to Allarity Therapeutics?

Which has higher valuation and earnings, CODX or ALLR?

Do insiders and institutionals have more ownership in CODX or ALLR?

Do analysts rate CODX or ALLR?

Does the media favor CODX or ALLR?

Is CODX or ALLR more profitable?

Which has more risk and volatility, CODX or ALLR?

Summary

How does Co-Diagnostics compare to Marker Therapeutics?

Which has higher earnings & valuation, CODX or MRKR?

Do analysts rate CODX or MRKR?

Does the media prefer CODX or MRKR?

Is CODX or MRKR more profitable?

Do institutionals & insiders hold more shares of CODX or MRKR?

Which has more risk & volatility, CODX or MRKR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CODX vs. The Competition

Co-Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools